Abiraterone is under clinical development by Austhera BioSciences and currently in Phase II for Hormone-Sensitive Prostate Cancer.

CSL -889 is under development for the treatment of acute vascular occlusive crisis (VOC) in sickle cell disease. The drug candidate consists of plasma-derived hemopexin. It is administered through ...

NUC-7738 is under clinical development by NuCana and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...

ENA-001 is under clinical development by Enalare Therapeutics and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Long-Acting Injectable Program is under clinical development by Intra-Cellular Therapies and currently in Phase I for Schizoaffective Disorder.

Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Myelodysplastic Syndrome.

AMT-162 is under development for the treatment of amyotrophic lateral sclerosis. It comprises of Adeno-associated virus rh 10 (AAVrh10) encoding an artificial microRNA (miRNA) that targets SOD1 and ...

HPV-16 E7 is under clinical development by Gilead Sciences and currently in Phase II for Oropharyngeal Cancer.

Enpatoran is under clinical development by Merck and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.

PAX-1 is under clinical development by Komipharm International and currently in Phase I for Head And Neck Cancer.

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Non-Small Cell Lung Cancer.

Amesanar is under clinical development by RHEACELL and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient ...